CMS advises Zukunftsfonds Heilbronn on sale of medical technology firm XENIOS to Fresenius Medical Care

Munich – zfhn Zukunftsfonds Heilbronn, one of Germany’s largest private venture capital providers, has sold Heilbronn-based XENIOS AG to Fresenius Medical Care AG & Co. KGaA (Fresenius Medical Care). XENIOS AG is an international medical technology company specialising in the treatment of lung and cardiac failure. The transaction is expected to be completed by the end of 2016, subject to approval by the competition authorities. Details of the purchase price were not disclosed.

A team from CMS headed by lead partner Stefan-Ulrich Müller, with Dr Tilman Weichert responsible for overall coordination, advised zfhn Zukunftsfonds Heilbronn on all legal aspects of the sales process.

zfhn Zukunftsfonds Heilbronn primarily supports young, innovative technology companies that are either already based in the Heilbronn region or prepared to relocate to the area in the short to medium term. Zukunftsfonds is privately financed and holds hundreds of millions of euros in equity. zfhn acquired Novalung GmbH, a manufacturer of artificial lungs, in 2008, followed by Medos Medizintechnik AG, a producer of state-of-the-art blood pump systems, in 2010. In 2013, the two companies were merged to form XENIOS AG, which now has more than 260 employees.

XENIOS is a leader in technology and therapies for minimally invasive lung and heart support. Minimally invasive treatments enable lung and cardiac assistance to be provided to patients who are awake, responsive and mobile. These treatments also ensure ventilator-associated lung injuries, pneumonia and atrophy of the breathing muscles are prevented.

Fresenius Medical Care is one of the world's leading providers of products and services for people with kidney diseases; around 2.8 million patients worldwide regularly undergo dialysis. The company treats 306,366 dialysis patients around the world through its network of 3,579 dialysis clinics. By extending its services to include the treatment of heart and lung diseases, Fresenius Medical Care aims to expand its world-leading position in extracorporeal organ support.

CMS Hasche Sigle

Stefan-Ulrich Müller, Lead Partner
Dr Petra Schaffner, Partner
Dr Tilman Weichert, Counsel, Coordination
Marcus Wuntke, Counsel
Dr Tobias Kallmaier, Senior Associate
Marcel Nurk, Associate, all Corporate/M&A
Gerd Schoenen, Partner, IP/Commercial
Dr Christian Scherer-Leydecker, Partner, Real Estate & Public
Stefan Lehr, Partner, Competition & EU
Roland Wutzke, Partner, Tax

Press Contact
presse@cms-hs.com